^
    over3years
    [VIRTUAL] Molecular High Grade (MHG) gene expression profile in DLBCL is enriched among patients with early treatment failure (ICML 2021)
    MHG was more frequently identified in the early progressor cohort, suggesting that MHG GEP contributes to poor response to conventional R-CHOP treatment for DLBCL. Prospective identification of this group for testing more effective treatment strategies is a priority.
    Clinical • Gene Expression Profile
    |
    HTG EdgeSeq Pan B-Cell Lymphoma Panel • HTG EdgeSeq Precision Immuno-Oncology Panel
    |
    Rituxan (rituximab)